Efficacy and safety of atorvastatin after pediatric heart transplantation

Journal of Heart and Lung Transplantation

Volumn 21, Issue 11, 2002, Pages 1213-1217

  Chin, Clifford ^a,b   Gamberg, Pat ^a   Miller, Joan ^a   Luikart, Helen ^a   Bernstein, Daniel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CREATINE; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART TRANSPLANTATION; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MALE; METABOLIC DISORDER; MYALGIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; CHILD; FEMALE; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; POSTOPERATIVE PERIOD; PYRROLES; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS;

EID: 0036845850     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00455-2     Document Type: Article

References (18)

1. Chin C., Rosenthal D., Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant. 4:2000;193-199.
2. Ballantyne C.M., Jones P.H., Payton-Ross C., Patsch W., Short H.D., Noon G.P., Gotto A.M., DeBakey M.E., Young J.B. Hyperlipidemia following heart transplantation Natural history and intervention with mevinolin (lovastatin) . Transplant Proc. 19:1987;60-62.
3. Ballantyne C.M., Radovancevic B., Farmer J.A., Frazier O.H., Chandler L., Payton-Ross C., Cocanougher B., Jones P.H., Young J.B., Gotto A.M. Hyperlipidemia after heart transplantation report of a 6-year experience, with treatment recommendations . J Am Coll Cardiol. 19:1992;1315-1321.
4. Keogh A., Simons L., Spratt P., Esmore D., Chang V., Hickie J., Baron D. Hyperlipidemia after heart transplantation. J Heart Transplant. 7:1988;171-175.
5. Rickenbacher P.R., Kemna P.R., Pinto F.J., Hunt S.A., Alderman E.L., Schroeder J.S., Stinson E.B., Popp R.L., Chen I., Reaven G., Valantine H.A. Coronary artery intimal thickening in the transplanted heart an in vivo intracoronary ultrasound study of immunologic and metabolic risk factors . Transplantation. 61:1995;46-53.
6. Park J.-W., Merz M., Braun P., Bermeltfoort M. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant. 15:1996;572-579.
7. Johnson M.R. Transplant coronary disease nonimmunologic risk factors . J Heart Lung Transplant. 11:(suppl):1992;S124-132.
8. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Steinbeck G., Seidel D., Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation. 96:1997;1398-1402.
9. Kato T., Tokoro T., Namii Y., Kobayashi T., Hayashi S., Yokoyama I., Morimoto S., Chan M., Giannetti N., Hunt S.A. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplant Proc. 32:2000;331-333.
10. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., Cogert G.A., Trosian K., Hamilton M.A., Moriguchi J.D., Kawata N., Hage A., Drinkwater D.C., Stevenson L.W. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
11. Penson M.G., Fricker F.J., Thompson J.R., Harker K., Williams B.J., Kahler D.A., Schowengerdt K.O. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant. 20:2001;611-618.
12. Pahl E., Crawford S.E., Wax D.F., Backer C.L., Mavroudis G., Gidding S. Safety and efficacy of pravastatin in pediatric heart transplant recipients. J Heart Lung Transplant. 20:2001;230.
13. Black D.M., Bakker-Arkema R., Nawrocki J.W. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 158:1998;577-584.
14. Magnani G., Carinci V., Magelli C., Potena L., Reggiani L.B., Branzi A. Role of statins in the management of dyslipidemia after cardiac transplant randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin . J Heart Lung Transplant. 19:2000;710-715.
15. Pahl E., Fricker F.J., Armitage J., Griffith B.P., Taylor S., Uretsky B.F., Beerman L., Zuberbuhler J.R. Coronary arteriosclerosis in pediatric heart transplant survivors limitation of long-term survival . J Pediatr. 116:1990;177-183.
16. Kuo P.C., Kirshenbaum J.M., Gordon J., Laffel G., Young P., DiSesa V.J., Mudge G.H., Vaughan D.E. Lovastatin therapy for hypercholesterolemia in cardiac transplantation. Am J Cardiol. 64:1989;631-635.
17. Keogh A., Macdonald P., Kaan A., Aboyoun C., Spratt P., Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant. 19:2000;529-537.
18. Abramowicz M. Choice of lipid-regulating drugs. Med Lett Drugs Ther. 43:2001;43-48.